MarketPulse — Real-Time Financial News & Market Analysis

Sanofi CEO Paul Hudson steps down February 17; Belén Garijo takes over post-AGM. Stock fell 4.5% on leadership transition announcement amid vaccine sales decline concerns.

Columbia Banking System increased its quarterly dividend to $0.37 per share, payable March 16, 2026, reflecting the company's commitment to returning capital to shareholders.

Novartis's kidney drug Vanrafia shows sustained efficacy in slowing kidney function decline, supporting its path to full regulatory approval in 2026 for IgA nephropathy treatment.

Rivian's stock surged 20% after beating Q4 expectations and raising 2026 delivery guidance to 62,000-67,000 vehicles, boosted by upcoming R2 SUV launch.

PodcastOne raised FY2026 revenue guidance to $60-62M following a major IP licensing deal with a Fortune 250 streamer for television adaptation.

Datatec to present at AI & Technology Conference February 19th, showcasing strategic growth through recent acquisitions in managed security services and Eastern European cybersecurity distribution.

Law firm Kaskela LLC investigates BARK Inc. over 60% stock decline, examining whether leadership violated securities laws or breached fiduciary duties to shareholders.

Law firm investigates European Wax Center's $5.80/share acquisition price, alleging potential fiduciary breaches. Analyst valued company at $15/share, suggesting possible undervaluation.

Citius Oncology reports maiden revenue of $3.9M from LYMPHIR immunotherapy launch in December 2025, marking transition to commercial-stage biopharmaceutical company.

Meltwater secures official Reddit data partnership to provide enterprise analytics on 121M daily users, enabling brands to monitor sentiment and trends from Reddit discussions.

Citius Pharma reports first revenue of $3.9M from LYMPHIR™ launch, raises $20.9M to support growth and advance pipeline candidates.

Nasus Pharma raises $15M to advance intranasal epinephrine product toward FDA trials. Funds support NS002 development and pipeline expansion.

Aardvark Therapeutics granted 152,338 stock options to six new hires with exercise prices of $13.48-$12.67, vesting over four years with a one-year cliff.

Law firm Kaskela initiates shareholder investigation into Priority Technology over 50% stock decline since February, examining potential securities violations and fiduciary duty breaches.

Law firm investigates Clearwater Analytics' $24.55/share PE acquisition, questioning if price fairly values shareholders given prior analyst targets above $35.

Dycom Industries will present FY2026 results on March 4, 2026, via conference call at 9:00 a.m. ET, with a press release and Q&A session for investors.

Three dividend aristocrats—Coca-Cola, Verizon, and Realty Income—offer stable income streams across consumer staples, telecom, and real estate sectors for long-term investors.

Soleus Capital significantly increased its Celcuity stake to 1.8 million shares, making it their third-largest position worth $180 million as the biotech stock surged 745% yearly.

Alphabet on track for $5T valuation by 2027 driven by AI adoption. Google Search hit record $63.1B quarterly revenue; Cloud division surged 48% year-over-year.

QLD offers tech-focused 2x leverage with higher volatility; SSO provides diversified S&P 500 exposure with lower costs. Both suited for tactical, short-term trading, not long-term investing.